The abstract is read at the publisher; the summary is JClub's.
Blood-based neurofilament light and phosphorylated tau 217 are being implemented in clinical practice for frontotemporal dementia, amyotrophic lateral sclerosis, and Alzheimer’s disease diagnosis.
- Why it matters: Rapid biomarker progress is needed to match the expanding treatment landscape and to address dementia’s diverse, overlapping pathologies and patient-to-patient variability in treatment response.
- What they did: The field has advanced through ultrasensitive multiplexing technologies and high-specificity antibodies, enabling multiple fluid biomarkers to reflect mechanisms and copathologies, including vascular, α-synuclein, and TDP-43.
- The result: Broader biomarker-pathology mapping in experimental models, plus expanded diagnostic methods, point-of-care tools, and remote sampling, should accelerate development and support clinical capture of full pathology complexity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.